We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exactech (EXAC) Scales a 52-Week High on Solid Q1 Results
Read MoreHide Full Article
Share price of Exactech Inc reached a new 52-week high of $25.86 on Jun 14. This represents a strong one-year return of approximately 23.5%, much better than the S&P 500’s return of -1% over the same period.
Currently, Exactech has a Zacks Rank #2 (Buy). The stock has a market cap of 359.87 million and a long-term expected earnings growth rate of 8.9%.
Growth Catalysts
Exactech reported impressive first-quarter 2016 results. Adjusted earnings of 31 cents per share beat the Zacks Consensus Estimate by a penny and increased almost 7% on a year-over-year basis.
The growth was driven by strong revenues, which increased 6.4% (7% at constant currency) to $65.3 million. All three major segments -- Extremities, Knee and Biologic & Spine -- reported revenue growth in the quarter.
Exactech noted that the full launch of proximal humeral reconstruction stem and investments in the U.S. sales organization helped in improving the company’s results. These along with the upcoming launches of three revision systems will drive growth in 2016 and beyond.
Encouraged by the impressive results, Exactech raised its full-year 2016 guidance. The company now expects revenues in the range of $250--257 Million. Adjusted earnings are forecasted in the band of $1.14 to $1.19 per share.
Estimate Revisions
However, the positives outweigh the negatives as evident from the recent trend of estimate revisions. The Zacks Consensus Estimate for fiscal 2016 increased by a penny to $1.17 over the last 60 days. Similarly, fiscal 2017 estimates increased by a couple of cents to $1.33 over the same period.
Key Picks
Better-ranked stocks in the broad medical sector include Masimo Corp (MASI - Free Report) , IRadimed (IRMD - Free Report) and CryoLife . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Exactech (EXAC) Scales a 52-Week High on Solid Q1 Results
Share price of Exactech Inc reached a new 52-week high of $25.86 on Jun 14. This represents a strong one-year return of approximately 23.5%, much better than the S&P 500’s return of -1% over the same period.
Currently, Exactech has a Zacks Rank #2 (Buy). The stock has a market cap of 359.87 million and a long-term expected earnings growth rate of 8.9%.
Growth Catalysts
Exactech reported impressive first-quarter 2016 results. Adjusted earnings of 31 cents per share beat the Zacks Consensus Estimate by a penny and increased almost 7% on a year-over-year basis.
EXACTECH INC Price and Consensus
EXACTECH INC Price and Consensus | EXACTECH INC Quote
The growth was driven by strong revenues, which increased 6.4% (7% at constant currency) to $65.3 million. All three major segments -- Extremities, Knee and Biologic & Spine -- reported revenue growth in the quarter.
Exactech noted that the full launch of proximal humeral reconstruction stem and investments in the U.S. sales organization helped in improving the company’s results. These along with the upcoming launches of three revision systems will drive growth in 2016 and beyond.
Encouraged by the impressive results, Exactech raised its full-year 2016 guidance. The company now expects revenues in the range of $250--257 Million. Adjusted earnings are forecasted in the band of $1.14 to $1.19 per share.
Estimate Revisions
However, the positives outweigh the negatives as evident from the recent trend of estimate revisions. The Zacks Consensus Estimate for fiscal 2016 increased by a penny to $1.17 over the last 60 days. Similarly, fiscal 2017 estimates increased by a couple of cents to $1.33 over the same period.
Key Picks
Better-ranked stocks in the broad medical sector include Masimo Corp (MASI - Free Report) , IRadimed (IRMD - Free Report) and CryoLife . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>